The BIKEN Group is a Specialty Bio-Pharmaceutical Organization
specializing in Vaccines.
In 2017, the Research Foundation of Osaka University, BIKEN Foundation, and BIKEN Corporation started a new chapter known as the “BIKEN Group.”
We will combine our strengths and work for better public health both in Japan and the entire world.
Press Release & Update
-
2023/09/27Press Release
VLPT Japan, Biken Foundation, Denka sign agreement to develop self-amplifying “replicon” RNA influenza vaccine
-
2023/09/14
VLPT Japan, Biken Foundation sign MoU on potential business alliance eying 2023 conclusion of “replicon” RNA COVID-19 vaccine production, sales license agreement
-
2023/06/19Notice
Announcement of BIKEN Group’s new board members
-
2023/03/27Press Release
Approval of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
-
2022/04/11Press Release
Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)
-
2019/11/11Press Release
Regarding the Incident of Vaccine Culture Fluid Leakage at Seto Office